Modeling biomarker kinetics of Aβ levels in serum following blast
Authors:
Open Access
- 4 April 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1548589
Abstract
Elucidating the unique neuropathological response to blast exposure remains a barrier towards the development of diagnostic approaches for those with blast-induced traumatic brain injury (bTBI). Quantification of biomarker concentrations in the blood post-injury is typically used to inform brain injury severity. However, injury progression and associated changes in biomarker concentrations are sensitive to parameters such as the blast overpressure (BOP) magnitude and frequency of blast exposure. Through this work, a blast-dose biomarker kinetics (BxK) platform was developed and validated for Aβ42 as a promising predictor of injury post-blast. Blast-dose responses accounting for BOP magnitude and frequency were integrated into a mathematical model accounting for whole-body Aβ peptide kinetics. Validation of the developed model was performed through comparison with acute monomer levels in the blood serum of 15 service members exposed to repeated low-level blast while undergoing three-day weapons training. Amyloid precursor protein (APP) synthesis was assumed to be proportional to blast magnitude and additive effects within a window of recovery were applied to account for cumulative exposure. Aβ42 concentrations in the blood serum were predicted within 6.5 ± 5.2% on average, demonstrating model feasibility and biomarker sensitivity to blast. Outcomes discuss how modulation of patient-specific factors (age, weight, genetic factors, years of exposure, sleep) and pathophysiological factors (BBB permeability, amyloidogenic pathology, neuroinflammation) can reveal potential sources of variability in experimental data and be incorporated into the blast-dose BxK platform in future iterations. Advancements in model complexity accounting for sex-specific factors, weapon system, stress levels, risk of symptom onset, and pharmacological treatment strategies are anticipated to improve model calibration. Utilization of this blast-dose BxK model to identify drivers of pathophysiological mechanisms and predict chronic outcomes has the potential to transform bTBI diagnostic, prognostic, and therapeutic strategies.Keywords
This publication has 80 references indexed in Scilit:
- Blast-Induced Biomechanical Loading of the Rat: An Experimental and Anatomically Accurate Computational Blast Injury ModelJournal of Neurotrauma, 2012
- Mechanics of blast loading on the head models in the study of traumatic brain injury using experimental and computational approachesBiomechanics and Modeling in Mechanobiology, 2012
- Acute Blast Injury Reduces Brain Abeta in Two Rodent SpeciesFrontiers in Neurology, 2012
- High Prevalence of Chronic Pituitary and Target-Organ Hormone Abnormalities after Blast-Related Mild Traumatic Brain InjuryFrontiers in Neurology, 2012
- MDR1–P-glycoprotein (ABCB1)-Mediated Disposition of Amyloid-β Peptides: Implications for the Pathogenesis and Therapy of Alzheimer’s DiseaseClinical Pharmacology & Therapeutics, 2010
- Traumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease?Nature Reviews Neuroscience, 2010
- Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's diseaseAlzheimer's & Dementia, 2009
- Apolipoprotein E: Far More Than a Lipid Transport ProteinAnnual Review of Genomics and Human Genetics, 2000
- The amyloid precursor protein of Alzheimer disease in human brain and bloodJournal of Leukocyte Biology, 1999
- Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets.1998